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Objective: A systematic review and meta-analysis of diagnostic biomarkers for
noninvasive diagnosis of acute allograft rejection following liver transplantation.
Background: Noninvasive blood and urine markers have been widely explored in recent
decades for diagnosing acute rejection after liver transplantation. However, none have
been translated into routine clinical use so far due to uncertain diagnostic accuracy, and
liver biopsy remains the gold standard.
Methods: Systematic literature searches of Medline, Cochrane and Embase were
conducted up to February 2019 to identify studies evaluating the use of noninvasive
markers in diagnosing allograft rejection following liver transplantation. Meta-analysis
was performed using a random effects model with DerSimonian–Laird weighting and
the hierarchical summary receiver operating curve.
Results: Of 560 identified studies, 15 studies (1,445 patients) met the inclusion
criteria. The following markers were tested: acid labile nitroso-compounds (NOx), serum
amyloid A protein, procalcitonin, peripheral blood eosinophil count, peripheral blood
T-cell activation and interleukin 2 (IL-2) receptor, guanylate-binding protein-2 mRNA,
graft-derived cell-free DNA, pi-glutathione S-transferase, alpha-glutathione S-transferase
and serum HLA class I soluble antigens. Only eosinophil count was tested in multiple
studies, and they demonstrated high heterogeneity (I² = 72% [95% CI: 0.5–0.99]). IL-2
receptor demonstrated the highest sensitivity (89% [95% CI: 0.78–0.96]) and specificity
(81% [95% CI: 0.69–0.89]).
Conclusion: IL-2 receptor expression demonstrated the highest diagnostic accuracy,
while the peripheral eosinophil count was the only marker tested in more than one study.
Presently, liver biopsy remains superior to noninvasive diagnostic biomarkers as most
studies exhibited inferior designs, hindering possible translation into clinical application.
Keywords: liver transplantation, acute rejection, diagnostic biomarker, diagnostic accuracy, non-invasive test
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INTRODUCTION
Liver transplantation (LT) exhibits 20-year survival rates of
up to 50% (1) and is of great clinical importance. LT is the
treatment of choice for acute or acute-on-chronic liver failure,
while organ replacement therapies are still waiting for the break
(2). LT is superior to liver resection in suitable patients with
hepatocellular carcinoma in cirrhosis, the most common primary
liver cancer and the second leading cause of cancer-related deaths
worldwide (3, 4).
Within the first few weeks after transplantation, patients are
at high risk of acute rejection (AR), with the incidence ranging
from 50 to 70% (5), depending on the immunosuppressive
regime selected. AR can be described as an immune response
against donor tissues resulting from T-cell recognition of allo-
antigens. This overwhelming immune response compromises
graft integrity and can lead to life-threatening graft loss. Thus,
AR is the most common cause of transplant failure and the
most common indication for re-transplantation. Indeed, the early
diagnosis of AR is crucial for successful anti-rejection therapy
and maintenance of graft function/integrity. The importance of
prompt AR diagnosis and management is increased due to an
organ shortage and an increasing proportion of marginal organs.
The liver graft and liver function can be monitored
by standard blood tests such as total bilirubin, alanine
aminotransferase, aspartate aminotransferase, γ-glutamyl
transpeptidase, and alkaline phosphatase. Leukocytosis and
eosinophilia are also frequently present (6). In addition, the
trough blood levels of immunosuppressive drugs can be
monitored and may predict AR risk (7). Nevertheless, standard
laboratory tests are nonspecific and are not suitable for the
efficient and timely diagnosis of AR (8). In the case of suspected
AR, liver biopsy with histologic specimen diagnosis and grading
remains the diagnostic tool of choice in routine clinical practice.
Nonetheless, liver biopsy is an invasive procedure associated with
severe complications primarily performed by trained colleagues
in transplant centers.
The concept of noninvasive measurement applies to
biomarkers in the saliva, peripheral blood, urine or other body
fluids (e.g., cytokines or surface proteins of different immune
cells) (8). Such diagnostic biomarkers have been explored to
replace liver biopsy and are predominantly used in the field
for diagnostic and monitoring purposes. The first attempt
to noninvasively diagnose allograft rejection in LT patients
occurred 30 years ago (9). Since then, numerous studies have
been published, but a single method has not yet been adopted
into routine clinical use. New biomarkers are compared with
liver biopsy in terms of their usefulness for diagnosing AR.
Markers for AR have to face sensitivity and specificity,
statistical measures that determine the applicability of diagnostic
tests. Sensitivity, the true positive rate, refers to how well a
test identifies transplant patients who are suffering from AR.
Specificity is the true negative rate and is of particular interest
because most known markers are not able to discriminate AR
from liver dysfunction, cytomegalovirus infection and hepatitis
C virus infections (8). Indeed, a diagnostic tool must be validated
for accuracy, otherwise its significance remains uncertain. In
addition, the test should be easily performed with results that are
available on the same day so that anti-rejection treatment may be
initiated as soon as possible.
Therefore, the aim of this study was to perform a systematic
review and meta-analysis evaluating the diagnostic accuracy of
noninvasive markers in the diagnosis of AR compared with
conventional liver biopsy in patients following LT.
METHODS
The systematic review was conducted according to
the Preferred Reporting Items for Systematic Reviews
(PRISMA) (10) guidelines and was registered with the
International Prospective Register of Systematic Reviews
(PROPSPERO: CRD42017072425).
Literature Search
The author searched MEDLINE (via PubMed), EMBASE and
the Cochrane Library electronic databases. No date restriction
was applied, and the literature search was performed in
August 2017 and updated in February 2019. The search terms
were initially reviewed by the author group and were sent
to an expert librarian to ensure completeness and accuracy
according to the PRESS Guideline Statement (11). The specific
search strategy for MEDLINE/PubMed conducted in January
2018 was: Search ((((((((((((((“acute rejection”) OR (“acute
allograft rejection”) OR (“acute graft rejection”) OR (“acute
liver allograft rejection”) OR (“acute reject∗”) OR (“acute
cellular rejection”) OR (ACR) OR (“early rejection”) OR (“early
reject∗”) OR (“early allograft rejection”) OR (“early graft
rejection”) OR (“early liver allograft rejection”) OR (“early
liver graft rejection”) OR (“early cellular rejection”)))) AND
((biomarker OR biomarkers OR marker OR non-invasive OR
liquid-biopsy))) AND (((liver transplantation) OR (liver graft∗)
OR (liver transplant∗)))) AND (((sensitiv∗[Title/Abstract]
OR sensitivity and specificity[MeSH Terms] OR (likelihood
ratio) OR odds ratio OR (OR) OR (predictive value) OR
AUC OR AUROC OR (area under curve) OR LR OR
diagnose[Title/Abstract] OR diagnosed[Title/Abstract] OR
diagnoses[Title/Abstract] OR diagnosing[Title/Abstract]
OR diagnosis[Title/Abstract] OR diagnostic[Title/Abstract]
OR diagnosis[MeSH:noexp] OR diagnostic ∗[MeSH:noexp]
OR diagnosis, differential[MeSH:noexp] OR
diagnosis[Subheading:noexp]))))))))))). The same search
strategy was applied for the Cochrane Library and EMBASE
as well.
Selection Criteria
Studies were included in the systematic review if they met the
following criteria:
• The study was designed as a diagnostic accuracy trial testing a
noninvasive biomarker(s) of AR in LT patients.
• AR was defined according to the International Consensus
Document on Terminology of Hepatic Allograft Rejection (6).
• The index test was primarily used to diagnose AR.
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• The study used liver biopsy and histopathological grading as
the reference test to diagnose AR.
• The study presented sufficient data to create a 2 × 2
contingency table.
• The study enrolled adult patients (≥18 years of age).
• The study was published in English.
Prediction of AR at some time in the future or the grading
of patient risk for AR at any time point following LT led to
study exclusion, because predicting the likelihood of AR in the
future is different than diagnosing AR in clinical practice where
anti-rejection therapy must be initiated on the same day as
diagnosis. Therefore, studies needed to specify the time interval
between sampling and confirmation of BPAR (biopsy-proven
acute rejection), ensuring that test samples were timely connected
to BPAR for analysis.
Study Selection and Data Extraction
All articles identified by the search were screened and excluded
if they did not meet the inclusion criteria. The full texts of
all potentially relevant studies were reviewed in detail. Data
was extracted using a predetermined standardized form and
included the following information: study design (cohort/single-
gate or case-control/multi-gate), characteristics of participants,
time of follow-up and regimen of immunosuppressive therapy.
Test validity was assessed by the total number of patients with
AR/no AR, prevalence of AR in the sample, and test parameters
including sensitivity, specificity, positive predictive value (PPV),
negative predictive value (NPV), likelihood ratio (LR), and area
under the curve (AUC).
Risk of Bias Assessment
The Revised Quality Assessment of Diagnostic Accuracy Studies
tool (QUADAS-2) was used to appraise the reliability and
applicability of the study findings (Supplementary Table 1) (12).
The signaling questions were carried out independently by two
reviewers (FK and EK). Any discrepancy between the reviewers
was resolved through discussion until a common conclusion was
achieved. The assessment tested for patient selection, index test,
reference standard, and study flow and timing. Each item was
answered by yes, no or unclear, indicating a high, low or unclear
risk of bias.
Statistical Analysis
Contingency tables were constructed based on values for
sensitivity, specificity and corresponding sample size given in
the studies. The extracted data was then used to calculate the
PPV, NPV, and the positive and negative LR for each test
when not reported in the manuscript. Confidence intervals were
demonstrated with forest plots (13).
After critical appraisal, a meta-analysis was conducted to pool
study estimates of specific markers. All pooled outcomemeasures
were determined using the random effect model described
by DerSimonian and Laird. The risk ratio (RR) of patients
positive for eosinophilia against the risk of patients negative for
eosinophilia to suffer fromAR after transplantation confirmed by
liver biopsy was estimated for each study. Heterogeneity among
studies was quantified using the I² statistic, which describes
the percentage of variation across studies due to heterogeneity
rather than chance (14). The RR of each study was plotted
against the respective measures of study size to investigate any
existing bias (15) and was visualized through a funnel plot. Lastly,
a hierarchical summary receiver operating curve (HSROC), as
described by Rutter and Gatsonis, was used to simultaneously
estimate the summary receiver operating curve (SROC) and the
expected operating point on the curve for the diagnostic accuracy
studies testing eosinophilia (16). All statistical analyses were
conducted using statistical software R (www.r-project.org), and
P < 0.05 was considered significant.
RESULTS
Of the initial 560 references retrieved from the databases, 104
were filtered for full-text review after the titles and abstracts were
screened. Of these, only 15 studies fulfilled all inclusion criteria
and were included in the systematic review. A PRISMAflow chart
depicting the flow of information through the different phases
of the literature review is shown in Figure 1. All studies were
published between 1994 and 2019.
Baseline Study Characteristics
The lead author’s name, study center, study design, studied index
test, follow-up period and sample size are listed for each included
study in Table 1. A risk of bias assessment using the QUADAS-
2 tool was carried out for all studies (12), and only 6 studies
exhibited low bias in all four parameters (Table 2). The overall
allocation of risk of bias of the included studies is graphically
depicted in Supplementary Figure 2. In total, 12 studies were
prospective consecutive cohort trials, 2 studies identifiedmarkers
by exploration and validation, and 1 study was retrospective in
design. Overall, 1,446 patients were analyzed by the included
studies, and all patients underwent LT due to different underlying
liver diseases.
Index tests were measured by taking peripheral blood samples
at specific pre- or post-transplant time points, and liver biopsies
were performed timely connected to the index tests. Note, liver
biopsy was used as the reference standard in all included studies
(n= 15). The markers identified by our review were eosinophilia
(4 studies, 805 patients), serum amyloid A protein (1 study, 12
patients), nitric oxide (1 study, 50 patients), alpha-glutathione S-
transferase (2 studies, 67 patients), pi-glutathione S-transferase (1
study, 44 patients), peripheral T-cells and soluble IL-2 receptor
(1 study, 119 patients), guanylate-binding protein 2 mRNA (1
study, 46 patients), graft-derived cell-free DNA (1 study, 115
patients), procalcitonin (1 study, 20 patients), and serum HLA
class I soluble antigens (1 study, 14 patients). Serum proteome
characterization and subsequent validation through ELISA were
performed in two studies. The study by Massoud et al. (24)
identified the following seven markers: serum amyloid A protein
(SAA), complement 4 (C4), fibrinogen, complement 1q (C1q),
complement 3, heat shock protein 60, and heat shock protein
70. The study by Okubo et al. (20) identified autoantibodies in
sera by fold change and intensity to charge one of the following
markers: multivesicular body protein 2B, potassium channel
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FIGURE 1 | Flow of information during study selection. The literature search was conducted in Medline, the Cochrane Library and Embase in February 2019. Of 560
identified records, 15 were selected for systematic review. Of the 104 full-text articles assessed for eligibility, 88 were excluded. Of note, only predicting the risk of AR
development, not diagnosing AR, was considered an exclusion criterion. This figure was designed according to the PRISMA-Statement (10).
tetramerization domain containing 14, voltage-gated subfamily
A regulatory beta subunit 3, and triosephosphate isomerase 1.
The primary assessed outcome was index test accuracy
(sensitivity, specificity, PPV, NPV, +LR, and –LR) in AR
diagnosis confirmed by liver biopsy. The index test was usually
performed on the same day or one day before liver biopsy. In 7
studies, the diagnostic accuracy was tested by the combination of
the index test and an additional liver function parameter.
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Noninvasive Marker Test Accuracy
and Meta-Analysis
All test parameters are listed in Table 3. When insufficient data
were provided in the studies, test parameters were calculated
using a conventional contingency table. Out of all the parameters
explored by the 15 included studies, soluble IL2-R, studied by
Lun et al. (22), demonstrated superior accuracy; in 119 patients
a threshold value of >631 IU/ml predicted AR with a high
sensitivity (81%) and a specificity of 89%. In addition, the study
was assessed as having a very low risk of bias according to the
QUADAS-2 tool and had a considerable sample size (Table 2).
Peripheral blood eosinophil count was analyzed in 4 studies
that included 805 patients and 1,076 sample points (21, 23, 26)
for meta-analysis. The studies were pooled in an HSROC to
illustrate the diametrical sensitivity and specificity (Figure 2).
Blood eosinophilia demonstrated a pooled sensitivity of 50%
(95% CI: 0.18–0.78) and specificity of 80% (95% CI: 0.62–
0.92). The DerSimonian–Laird random effect method was used
to test the overall effect of peripheral blood eosinophilia on
accurately diagnosing AR, and single study RRs were calculated:
patients positive for eosinophilia had a 1.56 times higher risk
(95% CI: 1.21–2.02) of AR compared with patients negative
for eosinophilia (p = 0.0006). The results are graphically
illustrated in a forest plot in Table 4. The heterogeneity
among the studies was moderately high (72%, calculated by
I2 statistics). Furthermore, RR and effect sizes were plotted
against each other in a funnel plot to demonstrate possible
asymmetry between the studies. The empty left side of the
graphic shows existing bias, the origin of which may have been
either publication bias, clinical heterogeneity or methodological
heterogeneity (Figure 3).
The sample size varied among the studies that tested
for eosinophilia and was not equally distributed. Rodriguez-
Peralvarez et al. (25) included 615 patients (76%), Wang et
al. (26) included 37 patients (5%), Barnes et al. (23) included
101 patients (13%), and Hughes et al. (21) included 51 patients
(6%). Furthermore, the time points for the index test varied
greatly. Wang et al. (26) studied blood eosinophilia as a marker
of late AR and performed the index test and reference test
later than 6 months following transplantation, whereas the other
three studies (21, 23, 25) analyzed samples taken within days
of transplantation.
Test Accuracy of Single Studies
Lun et al. (22) (69 AR cases, 119 samples) studied the accuracy
of lymphocyte subset distribution, expression of T-cell activation
markers and concentration of soluble interleukin-2 receptor
(IL-2R) as markers of AR. There was upregulation of the IL-
2R (CD25) on CD4+ and CD8+ T cells accompanied by an
increase in soluble IL-2R in patients with AR. Indeed, soluble
IL-2R exhibited the highest diagnostic efficiency on the day
of rejection (+LR 14.49, -LR 0.44) and when measuring the
difference between 3 days prior to and the day of rejection
(+LR 7.3, -LR 0.2). The specificity and sensitivity of a threshold
of >3,850 IU/ml on the day of AR was 96% (95% CI: 0.86–
0.99) and 56% (95% CI: 0.28–0.62), respectively; the PPV and
NPV were 83 and 85%, respectively. A threshold value of
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TABLE 2 | Assessing risk of bias and concerns regarding the applicability of diagnostic studies.
Study Risk of bias Concerns regarding applicability
Patient selection Index test Reference standard Flow and timing Patient selection Index test Reference standard
Nagral et al. (29)
Devlin et al. (17)
Feussner et al. (18)
Kuse et al. (19)
Okubo et al. (20)
Hughes et al. (21)
Lun et al. (22)
Barnes et al. (23)
Kobayashi et al. (5)
Massoud et al. (24)
Rodriguez-Peralvarez et al. (25)
Wang et al. (26)
Schütz et al. (27)
Dickson et al. (28)
Molajoni et al. (30)
The Quality Assessment of Diagnostic Accuracy Studies tool (QUADAS-2) was used to appraise trustworthiness and applicability of the study findings (12). The signaling questions
were carried out independently by two reviewers (F.K. and E.K.). Any discrepancy between the reviewers was resolved through discussion until a common conclusion was achieved.
The analysis found that Barnes et al. (23), Nagral et al. (29), Kuse et al. (19), Lun et al. (22), Rodriguez-Peralvarez et al. (25), and Wang et al. (26) exhibited low risk.
.
>631 IU/ml (the difference between 3 days prior to and the
day of rejection) yielded the highest sensitivity and specificity
values (81% [95% CI: 0.69–0.89] and 89% [95% CI: 0.78–0.96],
respectively). The cut-off values were determined using the ROC
curve. A multivariate analysis was performed to improve the
diagnostic efficacy by a combination of best markers. However,
IL-2R on day of biopsy, time course of IL-2R, and CD4
between 3 days before biopsy and the day of biopsy showed
a correct classification of 71%, demonstrating no improvement
over soluble IL-2R alone. Of note, the given and calculated PPV
and NPV values differed. The risk of bias of the study was very
low (Table 2).
Schütz et al. (27) (17 AR cases, 107 samples) studied graft-
derived cell-free DNA in 107 patients undergoing LT due to
various underlying liver diseases. Only samples taken ≤6 days
before or 1 day after biopsy were considered for analysis. Graft-
derived cell-free DNA was obtained in stable patients, HCV+
patients and patients suffering from AR. The percentage was
significantly elevated (29.6% [95% CI: 0.23–0.41]) compared
with HCV+ patients (5.9% [95% CI: 0.04–0.11]) and stable
patients (3.3% [95% CI: 0.03–0.037%]; p < 0.001). Moreover, the
authors compared the diagnostic ability of graft-derived cell-free
DNA to that of normal liver function testing and demonstrated
independent information on graft integrity. Graft-derived cell-
free DNA with a threshold of 10% yielded a sensitivity of
90.3 (95% CI: 0.74–0.98) and specificity of 92.9% (95% CI:
0.89–0.95). However, the study was high in bias due to unclear
exclusion criteria (13 patients were excluded without reasonable
explanations; Table 2). Moreover, they did not include HCV+
patients with stable patients when analyzing for sensitivity
and specificity. Hence, that led to a significant decline in test
accuracy and increase in the threshold when they compared
HCV+ patients to patients with biopsy-proven AR (sensitivity
75% [95% CI: 0.55–0.89]; specificity 84.2% [95% CI: 0.71–
0.92]).
Feussner et al. (18) (14 AR cases, 42 samples) studied serum
amyloid A protein (SAA) and found a high positive LR (16.67).
The sample size of the study was small and demonstrated a
sensitivity of 66.7% (95% CI: 0.35–0.9) and specificity of 96%
(95% CI: 0.97–1). There was no pre-specified threshold, and
a cutoff point of 17 mg/dl was derived from the ROC curve.
Interestingly, no statistical correlation was found between SAA
and CRP (n= 37; r = 0.237; p= 0.157).
Dickson et al. (28) (14 AR cases, 44 samples) studied alpha-
glutathione S-transferase (alpha-GST) and pi-glutathione S-
transferase (pi-GST) as potential markers of hepatocyte and
biliary epithelial cell injury, which are considered possible
indicators of AR. Alpha-GST was found to have a positive LR of
7.5 and a negative LR of 0.54, with a sensitivity of 50% (95% CI:
0.23–0.76) and specificity of 93% (95% CI: 0.78–0.99). Patients
with no and mild rejection were grouped and compared with
those with moderate and severe rejection; however, mean values
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FIGURE 2 | Hierarchical summary receiver operating characteristic (HSROC) curve for eosinophilia. The HSROC curve composed of studies examining the diagnostic
value of eosinophilia in noninvasively diagnosing acute allograft rejection in patients undergoing liver transplantation is shown. Each individual study is represented by a
circle; the blue line represents the confidence interval, and the red line represents the credibility interval.
TABLE 4 | Meta-analysis for the test validity of peripheral blood eosinophilia in diagnosing acute allograft rejection.
Index test + Index test − Risk ratio (95% CI)
Study TP Total FN Total Weight Risk ratio (95% CI)
Hughes et al. (21) 27 37 9 36 0.13 2.92 (1.60–5.31)
Wang et al. (26) 11 13 13 27 0.18 1.76 (1.12–2.77)
Barnes et al. (23) 53 65 113 210 0.34 1.52 (1.28–1.80)
Rodriguez-Peralvarez et al. (25) 104 147 134 231 0.36 1.22 (1.05–1.42)
Total (95% CI) 262 504 1 1.56 (1.21–2.02)
Each study is shown by the point estimate of the risk ratio (RR) and the respective 95% confidence interval (CI), represented by the lines. The RR was calculated using the true positive
(TP) value for blood eosinophilia and total number of eosinophilia-positive patients for the index test-positive group (TP/Total+) and the false positive (FP) value for blood eosinophilia
and total number of eosinophilia-negative patients for the index test-negative group (FP/Total–). The combined RRs and CIs are represented by the diamond. The DerSimonian and
Laird random effect model was used. I2 statistics was used as a measure of heterogeneity. A statistically significant overall effect was obtained (P = 0.0006). Heterogeneity: Tau2 =
0.04; Chi2 = 10.89; df = 3 (P = 0.01); I2 = 72%. Test for overall effect: Z = 3.44 (P = 0.0006).
of alpha-GST and pi-GSTwere indistinguishable between the two
groups (data not shown in the manuscript).
Barnes et al. (23) (166 AR cases, 275 samples), Rodriguez-
Peralvarez et al. (25) (238 AR cases, 690 samples), Wang et al.
(26) (24 AR cases, 40 samples), and Hughes et al. (21) (36 AR
cases, 71 samples) all studied the peripheral blood eosinophil
count as a noninvasive marker of AR. Three of them (21, 23,
25, 26) had very low bias (Table 3). Wang et al. had the highest
positive LR (3.67), followed by Barnes et al. and Hughes et
al. Barnes et al. demonstrated the highest specificity (% [95%
CI: 0.81–0.94]) at an absolute eosinophil count (AEC) cut-off
value of 0.145 × 109, but reported a very low sensitivity (32%
[95% CI: 0.24–0.39]). Hughes et al. demonstrated a high NPV
(94%) and the highest sensitivity (76% [95% CI: 0.57–0.87]);
however, the pre-specified threshold led to a high risk of bias.
Wang et al. also stated that an AEC of 0.145 × 109 and a
relative eosinophil count (REC) of 2.3% demonstrated the highest
Youden index, with areas under the ROC curves of 0.746 and
0.813, respectively. Furthermore, an REC of >2.3% was able to
predict late AR (time point>6 months after LT) with a specificity
of 87.5% and a sensitivity of 75%. Although REC shows higher
accuracy parameters, the AEC was used in Table 3 to preserve
unanimity within the studies of eosinophilia. Furthermore,
Barnes et al. and Rodriguez-Peralvarez et al. studied the accuracy
of the AEC vs. the change in eosinophil count in predicting
the improvement or deterioration of the histological grade of
rejection as a response to treatment in a subgroup of patients who
underwent a second biopsy (n = 45 and n = 89, respectively).
Barnes et al. found no significant difference in the AEC or
the REC among those patients who subsequently improved,
remained stable or deteriorated histopathologically following
corticosteroid therapy; whereas, Rodriguez-Peralvarez et al.
discovered that the change in AEC between the first and second
biopsies was closely correlated with the histological course of AR
(AUC 0.72 [95%CI: 0.66–0.78]). Of note, the data fromHughes et
al. and Rodriguez et al. showed disagreement between the stated
and extracted PPVs and NPVs by conventional contingency
table (21, 25).
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FIGURE 3 | Funnel plot for the meta-analysis of studies testing eosinophilia as
a noninvasive biomarker. Relative risk (RR) was plotted against the standard
error (SE) of each study. The outcomes are represented by dots. Evidence of
considerable bias is demonstrated.
Devlin et al. (17) (33 AR cases, 55 samples) studied plasma
concentrations of the acid-labile nitroso-compound (NOx) as
a possible marker (+LR 3.20; –LR 0.06). They demonstrated
that NOx increased during AR (p < 0.0001) in association with
histopathological grading and decreased after administration of
glucocorticoids. It is unclear from the manuscript whether a
threshold was predetermined for NOx, which would interfere
with the reliability of the test accuracy. In addition, the
author studied the relationship between NOx and circulating
TNF-alpha and IL-2R, with a predetermined threshold for
circulating TNF-alpha.
Studies of Okubo et al. (20) (20 AR cases, 80 samples) and
Massoud et al. (24) (33 AR cases, 62 samples) were similarly
designed. The authors used proteomics and ELISA to test blood
samples to discover possible markers of AR. In both studies,
the discovery set was composed of patients undergoing LT due
to hepatitis C infection (with or without histopathological signs
of AR). Note, Okubo et al. also included patients with liver
dysfunction and healthy volunteers without any signs of AR.
Next, a completely separate group of patients was set up for
validation (ELISA) of markers that were revealed in the discovery
set. The validation panel were still sub-grouped into patients with
AR and patients without AR after LT. Massoud et al. identified
41 proteins, while C4 and C1q were both independent predictors
for AR with sensitivities of 97% (95% CI: 0.79–0.99) and 56%
(95% CI: 0.35–0.76) and specificities of 62% (95% CI: 0.38–
0.81) and 86% (95% CI: 0.64–0.97), respectively. A noteworthy
secondary outcome was the increased marker specificity of 81%
and sensitivity 96%when C4 (cut-off< 0.31 gm/L) was combined
with ALT (cut-off> 70 IU/ml). Taken together, C4 demonstrated
the best test accuracy in differentiating patients with and without
AR. Okubo et al. performedmicroarray analysis and identified 57
autoantibodies that were upregulated in the AR group; he then
selected four autoantibodies (multivesicular body protein 2B
[CHMP2B], KCTD14, voltage-gated subfamily A regulatory beta
subunit 3 [KCNAB3] and triosephosphate isomerase 1 [TPI1])
by fold change and antibody intensity. KCNAB3 was found
to be significantly higher in the AR group compared with the
group with liver dysfunction and no AR (+LR 2.25; –LR 0.17).
CHMP2B and TPI1 were both significantly overexpressed in the
AR group compared with the other control groups. The levels of
these antibodies increased only around the time of acute cellular
rejection, making them good candidates for diagnostic molecular
markers. CHMP2B showed outstanding performance, with an
AUC of 0.86 (95% CI: 0.75–0.97) and 80% specificity and 80%
sensitivity at a cut-off value of 0.33.
Kuse et al. (19) (10 AR cases, 40 samples) tested whether
procalcitonin (PCT) allowed differentiation between infection
and AR in cases of fever following LT. The authors demonstrated
that PCT had a high predictive value in differentiating between
AR and infection, with an AUC of 0.93. The highest sensitivity
and specificity values were found at a cut-off of 5.9 ng/ml, with
100% sensitivity (95% CI: 0.71–1) and 75% specificity (95% CI:
0.56–0.9). Renna Molajoni et al. (30) (8 AR cases, 16 samples)
studied whether serum HLA class I antigen was associated with
AR: a cut-off value of >2.1 g/ml yielded a sensitivity of 100%
(95% CI: 0.63–1) and a specificity of 75% (95% CI: 0.35–0.97).
However, both studies had low reliability due to underpowered
sample sizes and restricted inclusion criteria.
Nagral et al. (29) (38 AR cases, 56 samples) evaluated the
efficacy of alpha-GST as a marker of AR in comparison with
standard liver function tests (ALT and bilirubin). At a cut-off
value of >11.4, alpha-GST demonstrated a sensitivity of 63.1%
(95% CI: 0.45–0.78) and a specificity of 38.8% (95% CI: 0.17–
0.64); whereas, ALT (cut-off >40 IU/ml) yielded a sensitivity
of 97.4% and specificity of 16.6%. Alpha-GST was also tested
as a marker of successful anti-rejection therapy in 16 patients.
However, alpha-GST only decreased in 7 of 10 cases following
anti-rejection therapy (p = 0.9) and, thus, was not linked to
histological improvement.
Kobayashi et al. (5) (19 AR cases, 46 samples) analyzed the
diagnostic efficacy of guanylate-binding protein 2 mRNA (GBP2)
and interferon regulatory factor 1 mRNA (IRF1) as markers of
AR using real-time PCR. Patients with liver dysfunction (LD)
were included and further subgrouped into LD with AR vs.
LD without AR patients. Although both IRF1 and GBP2 were
higher in patients with LD (independent of AR) than in controls,
only GBP2 was higher in LD with AR patients compared to LD
without AR patients (+LR 4.2; –LR 0.43). A cut-off value of 20
produced a sensitivity and specificity of 63% (95% CI: 0.38–0.83)
and 85% (95% CI: 0.66–0.95), respectively. A noteworthy result
was that GBP2 was unable to distinguish between AR and HCV
recurrence (p = 0.2). The study was high in bias for patient
selection because of inappropriate patient exclusion (subjective
exclusion criteria, e.g., “rejection, infection, or recurrence of
primary disease”), which may have led to an overestimation of
study findings (Table 2).
DISCUSSION
The present systematic review andmeta-analysis has summarized
the current status of noninvasive diagnostic biomarkers to
diagnose AR following LT and, in doing so, has identified the
Frontiers in Immunology | www.frontiersin.org 10 April 2019 | Volume 10 | Article 758
Krenzien et al. Diagnostic Biomarkers in Liver Transplantation
best-evaluated diagnostic parameters. In total, 10 blood markers
were identified to diagnose AR, while the AEC was validated
by most studies and soluble IL-2R exhibited superior study
results. In the following paragraphs, we will discuss the most
important challenges currently limiting the establishment of a
noninvasive diagnostic markers in the diagnosis of AR after
liver transplantation.
A summary of the study exclusion criteria can be found
in Supplementary Figure 1. When we initially designed the
present systematic review, we did not anticipate the number of
studies that would not consider test accuracy (e.g., sensitivity and
specificity) or timely connect the reference test to the index test
(16% and 8%, respectively). Test accuracy is essential in assuring
study comparability and performance. The timely correlation
between the reference test and the index test is also important
as anti-rejection therapy should be initiated on the same day as
diagnosis. Therefore, appropriate methods and statistical tests
remain of utmost importance for the translation of findings
into routine clinical practice. However, when we reviewed the
literature, more than 95% of all screened studies did not consider
these two fundamental characteristics.
It appears plausible that among the 10 identified markers, IL-
2R expression in peripheral blood leukocytes, with a sensitivity,
specificity, NPV and PPV all above 80% and a considerable
sample size (119 patients), demonstrated the most promising
diagnostic accuracy for translation into clinical use. This was
underscored by the trial set up, patient criteria and very low
risk of bias. Although it did not show as strong a diagnostic
accuracy, peripheral blood eosinophilia was studied by Hughes
et al. (21), Wang et al. (26), Rodriguez-Peralvarez et al. (25),
and Barnes et al. (23), who included considerable sample sizes
and consequently had high reliability of their results. Rodriguez-
Peralvarez et al. demonstrated a significant correlation between
AEC and histological improvement in response to anti-rejection
therapy (25), whereas Barnes et al. found no statistically
significant change in AEC in response to treatment (23). The
discrepancy in study results for the utility of peripheral blood
eosinophilia in accurately differentiating between different grades
of rejection and for predicting histopathological improvement
after appropriate anti-rejection therapy may be due to the
considerable difference between the two studies’ sample sizes,
487 vs. 45. Another contributing factor may be the sample
grouping into no–mild rejection and moderate–severe rejection
groups, which could have led to bias. In conclusion, peripheral
blood eosinophilia was the most frequently tested marker, but
its clinical use as a single marker of AR is not supported
due to low data accuracy. However, eosinophilia might be
useful as a complementary test to indicate the need for closer
noninvasive monitoring of transplant patients for possible
liver biopsy.
Schütz et al. (27) studied graft-derived cell-free DNA in the
largest cohort study but also excluded patients for undefined
reasons. Test accuracy was high, although HCV+ patients
were excluded from stable patients in the sensitivity and
specificity analyses. Indeed, test accuracy decreased significantly
when HCV+ patients were included, yielding a sensitivity of
75% and specificity of 84.2%. Taken together, the concept of
graft-derived cell-free DNA is promising, although the study
design was imprecise.
In a few studies, true positive, false positive, true negative
and false negative values were used to calculate diagnostic
accuracy, and the sensitivity, specificity, PPV, NPV, LR, and
RR were either not stated at all or only partially stated.
Furthermore, Hughes et al. and Rodriguez et al. showed
inconsistency in the stated and derived PPV and NPV values,
raising concerns about the reliability of the reported AEC data
(21, 25). Therefore, the statistical error obviously increased as
we constructed contingency tables for our own calculations
with missing accuracy values. Indeed, calculated sensitivity,
specificity, PPV and NPV values did not always match the stated
values (21, 22, 25).
Six studies (19, 22, 23, 25, 26, 29) were assessed as having
low risk of bias, while nine studies (5, 17, 18, 20, 21, 24,
27, 28, 30) were found to have high risk of bias in all
tested categories. Study results could have been affected by
inappropriate patient exclusion strategies, previously defined
threshold values, inappropriate patient flow and timing.
No pediatric study (n = 27) did match our inclusion criteria.
Most reviewed studies do not include adults and children at the
same time, wherefore a possible particular finding will not be
applicable to both, the young and the old transplant recipients.
There are differences of the incidence of acute rejection with
increasing age (31). In addition, there are changes in immune
response with age, why some e.g. cytokines are low in young
age, but high in old age (31). Furthermore, immunosuppressive
regime is more complex in pediatric patients with longer
expected period of intense immunosuppression and changes in
pharmacokinetics in older patients (32). Therefore, we did not
consider pediatric patients in our systematic review.
In addition to the study design, another important factor
currently limiting the success of recent and past studies is the
lack of a robust endpoint that plays a crucial role in objectively
assessing the diagnostic efficacy of a particular biomarker. Liver
biopsy is the gold standard for the diagnosis of acute rejection
and the Banff Working Group on Liver Allograft Pathology
has defined histopathological finding of AR (33). Nevertheless,
percutaneous biopsy and diagnosis of AR is characterized by a
lack of reproducibility between experienced and inexperienced
pathologists (34, 35). Most diagnostic biomarkers consist of
proteins, which are elevated not only in AR, but also during
inflammation and infectious diseases, thus greatly lacking in
specificity (e.g., IL-2). Bacterial, viral and fungal infections
are one of the most common and challenging complications
following LT. While the immunosuppressive regimens do not
vary substantially between different solid organ transplantations,
similar infection patterns and pathogens can be encountered
(36). The postoperative course of liver transplant patients is
often complicated by various infections like reinfection with
hepatitis B and C viruses. In addition, every infection can timely
overlap with AR episodes, rendering the differential diagnoses
and treatment difficult. Most studies do not consider this
particular problem to differentiate between AR from infection.
For instance, AR and recurrent hepatitis C often coexist at
the same time (37). A multicenter study performed by Regev
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et al. tested the reliability of histopathologic findings between
recurrent HCV infection and AR (38). The colleagues unraveled
low interobserver and intraobserver agreement rates, with a
kappa score of smaller than 0.4. The same diagnostic uncertainty
exists with recurrence of autoimmune hepatitis (AIH) and the
occurrence of de novo autoimmune hepatitis (dnAIH) after
liver transplantation, which can both lead to graft dysfunction
if not timely treated. Interestingly, history HCV infection and
interferon gamma therapy are both related to dnAIH occurrence
post-transplantation (39). Moreover, study of the inflammatory
infiltrates in the livers of transplant pediatric patients showed
that antibodies against T-bet (transcription factor of T helper
cells 1) was lower in dn-AIH than in the AR and AIH group
(40). Risk of recurrence of AIH post-transplantation is related
to risk factors such as HLA-DR3 or HLA-DR4 positivity (41)
and early withdrawal of corticosteroids (42, 43). Taken together,
autoimmunity and infection can change histological findings and
make it difficult to diagnose AR by histology. This is analogue to
an ideal biomarker that must not only diagnose the AR, but also
be able to correctly differentiate to existing inflammatory states.
Note, failure to differentiate between infection, recurrent HCV
and AR may result fatal cumbersome by immunosuppression
that orchestrate immune response and perifocal immunological
changes (44, 45).
A stratification analysis was considered in order to examine
the studies in separate sample size layers to test for heterogeneity.
However, while only 4 studies were considered for the meta-
analysis, stratification would lead to low number with reduced
subgroups. Since the estimation of the degree of heterogeneity
in a model with random effects depends to a large extent on the
number of studies, a stratification means smaller subsets with
worse estimates of the amount of heterogeneity (46). The sample
sizes of the studies included in the meta-analysis are: 71, 40,
275, 690. Hence, a stratification in two or more groups cannot
be made meaningfully. Therefore, we decided to quantify the
heterogeneity between the studies using the random-effect model
described by DerSimonian and Laird (47).
CONCLUSION
The present review and meta-analysis systematically overviews
research on the use of noninvasive markers to diagnose AR
after LT. Interestingly, although only tested in one study, IL-
2R exhibited superior sensitivity/specificity underscored by a
decent sample size and low bias for all screened parameters.
Nevertheless, liver biopsy remains superior to the noninvasive
approach of diagnostic biomarkers as most of the marker study
designs were inferior, hindering the possible translation of this
noninvasive technique into routine clinical use at this time.
This is complicated by the fact, that a robust endpoint for
AR is missing and the evaluation of histopathological findings
of AR are influenced by intra- and interobserver variability
and occurring infections. Therefore, an appropriate clinical trial
design for validating the diagnostic accuracy of a potential
noninvasive marker for diagnosing AR remain indispensable.
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included in the meta-analysis. Of the initial 560 references retrieved from the
databases, 104 were filtered for full-text paper review after title and abstract
screening. Of these, 15 studies fulfilled all inclusion criteria and were included in
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(QUADAS-2) (12) was used to evaluate concerns regarding the risk of bias and
applicability of study findings. The signaling questions were answered according
to the judgment of two independent reviewers. Concerns regarding study
applicability were low for all studies (>90%), while risk of bias varied for different
components. Overall, the highest bias was found for patient flow and timing, and
the lowest bias was for the index test.
Supplementary Table 1 | Items relevant to the Quality Assessment of Diagnostic
Accuracy Studies tool QUADAS-2 protocol.
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